NCT07116746
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
Active, Not Recruiting
PHASE2Ages 18–85InterventionalTreatmentArthrosi Therapeutics
~15 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:AR882 75 mgXOI Low DoseXOI High Dose
At a glance
Recruiting sites
0 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6
Measured over 24 weeks
Conditions
Where it's being run
8 sites across 6 statesFlorida3
Mississippi1
North Carolina1
Pennsylvania1
Texas1
Washington1
Study leadership
- Robert Keenan, MD · STUDY_DIRECTOR · Arthrosi Therapeutics, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
History of uncontrolled gout
Presence of ≥1 clinically visible tophus
Last uricase infusion occurred ≥3 months
Body weight no less than 50 kg
Serum creatinine must be \< 3.0 mg/dL and estimated CLcr ≥ 40 mL/min
Exclusion
Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
Pregnant or breastfeeding
History of symptomatic kidney stones within the past 6 months
Received pegloticase, rasburicase or other experimental uricases within the last 3 months
What this trial measures
- Serum urate (uric acid) (sUA) level < 6 mg/dL at month 624 weeks
Proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL at month 6